The Boston-based startup will use the funds to expedite prototype development of its sample preparation technology and computational approach.
The firm had also applied for marketing clearance for its gram negative and fungal pathogen panels in October.
The company is developing a new gold standard comparator test after it encountered problems with typical culture methods it used in developing a new pneumonia assay.
The FDA cleared BD's test for detecting carbapenemase-producing organisms, which can be used by hospitals to contain the spread of antimicrobial resistance.
The firm signed four new distribution deals to spread its products into more than a dozen new markets.
The company is in discussions with the FDA about a new test being developed for severe bacterial pneumonia and expects to start a clinical trial in Q1 2019.
The firm beat Wall Street analyst estimates for revenues and earnings per share in the third quarter.
The updated FebriDx test utilizes an all-in-one plastic housing technology and requires no additional equipment to run the test or interpret results.
The firm beat analysts' revenue expectations for the quarter while its net loss was in line with predictions.
The method could allow clinicians to more rapidly determine the best course of antibiotic treatment for patients with sepsis and other bacterial infections.